De Novo and Relapsing Glomerular Diseases After COVID-19 Vaccination: What Do We Know So Far?

Vaccination is currently the central strategy to end the COVID-19 pandemic. Recently, cases describing new onset or flares of podocytopathies and glomerulonephritides after vaccination against SARS-CoV-2 have been reported and regulatory agencies are discussing if these adverse events should be included in the label. This editorial by Bomback, Kudose and D’Agati nicely summarizes the current knowledge. We should be aware of this new connection and systematically report it to our national agencies.